-
公开(公告)号:US6132751A
公开(公告)日:2000-10-17
申请号:US150
申请日:1998-02-03
申请人: Hidekazu Suzuki , Satoshi Yamazaki , Yoshikazu Naito , Takahiro Wada , Kaei Nagoshi , Noriko Tahira , Reiko Hirata , Touru Oguma , Makoto Maeda
发明人: Hidekazu Suzuki , Satoshi Yamazaki , Yoshikazu Naito , Takahiro Wada , Kaei Nagoshi , Noriko Tahira , Reiko Hirata , Touru Oguma , Makoto Maeda
CPC分类号: A61K31/573 , A61K9/0048
摘要: An O/W emulsion composition for eye drops comprises a drug selected from the group consisting of fluorometholone, clobetasone butyrate and clobetasol propionate; a phospholipid; liquid paraffine; and water. The O/W emulsion composition is excellent in solubility of fluorometholone, clobetasone butyrate and clobetasol propionate in the tear fluid. Therefore, the composition would exhibit an anti-inflammatory activity identical to or superior to those achieved by the conventional pharmaceutical preparations, by the administration thereof at a dose lower than those for these known drugs. The composition would also be excellent from the economical standpoint and permit reduction of systemic side effects which would be encountered when the conventional drugs are instilled in the eyes.
摘要翻译: PCT No.PCT / JP96 / 02187 Sec。 371日期1998年2月3日 102(e)1998年2月3日PCT PCT 1996年8月5日PCT公布。 公开号WO97 / 05882 日期:1997年2月20日用于眼药水的O / W乳液组合物包含选自氟米隆,丁酸氯倍他丁和丙酸氯倍他索的药物; 磷脂; 液体石蜡; 和水。 O / W乳液组合物在泪液中的氟米龙,丁酸氯倍他丁和丙酸氯倍他索的溶解度优异。 因此,通过以比这些已知药物低的剂量给药,组合物将表现出与常规药物制剂相同或优于常规药物制剂的抗炎活性。 从经济角度看,组合物也是优异的,并且允许减少常规药物滴入眼睛时会遇到的全身副作用。